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Introduction
Interactions between cancer and immunity have been inten-
sively studied during the past 2 decades (1, 2). However, mecha-
nisms hindering efficient constitutive and/or treatment-induced 
immune responses to human tumors have yet to be closely scru-
tinized. With rising incidence rates, bladder cancer (BCa) rep-
resents the fourth most commonly diagnosed cancer in men in 
Europe and the United States (3). Notably, BCa is the most expen-
sive malignancy to treat per patient (4), mostly on account of dra-
matically high recurrence rates requiring lifelong follow-up with 
multiple surgical procedures. Most patients (>70%) present with 
a non-muscle–invasive BCa (NMIBC) at diagnosis, i.e., cancer 
that is confined to the mucosa (stage Ta, carcinoma in situ [CIS]) 
or submucosa (stage T1) (5). A major aim in the management 
of urothelial carcinoma is the prevention of the recurrence and 
progression of disease. For patients with an intermediate to high 
risk of recurrence, the standard treatment consists of intravesical 
instillations with the bacillus Calmette-Guérin (BCG) to prevent 
or delay tumor recurrence and progression (5). However, 20% to 
30% of patients experience early recurrence, despite BCG treat-
ment, and eventually undergo surgical removal of the bladder 
(5, 6). Several decades after this empirical immunotherapy was 
approved by the US FDA (7), the mode of action of intravesical 
BCG therapy remains unclear (8). Yet, it was shown that the strong 
inflammation induced locally encompasses (a) secretion of vari-
ous chemokines and cytokines (9) and (b) infiltration of innate and 
adaptive immune cells, mostly neutrophils, T cells, and monocytic 
cells (8). This highlights the crucial need to better understand the 
regulation of immune responses that occur during the treatment 
of patients with NMIBC in order to identify new targetable path-
ways to improve BCa therapy.
In this prospective study, we performed a comprehensive 
analysis of immune cells in the urine of patients during BCG ther-
apy, which increases the immune cell content locally. We found 
that the ratio of T cells to monocytic myeloid-derived suppressor 
cells (M-MDSCs), known to dampen antitumor immunity (10, 11), 
is strongly associated with recurrence-free survival outcomes. Of 
note, BCG treatment does not seem to alter this ratio. We also 
identified, for the first time to our knowledge in a human cancer, a 
putative role for group 2 innate lymphoid cells (ILC2), which were 
recently described as the innate counterpart of Th2 cells (12, 13). 
ILC2 levels correlated with M-MDSC levels in urine upon treat-
ment with BCG. In vitro, bladder tumor cells and BCG were able 
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were sorted (Supplemental Figure 
1; supplemental material available 
online with this article; https://
doi.org/10.1172/JCI89717DS1), 
and mRNA was extracted for 
quantitative PCR (qPCR) analy-
ses. As shown in Figure 1E, CD14+ 
CD33+HLA-DRlo urine–sorted cells 
were found to express higher lev-
els of CCAAT/enhancer-binding 
protein β (C/EBPβ), an MDSC- 
associated transcription factor gov-
erning their suppressive function 
(14), compared with their CD33+ 
HLA-DRhi counterparts. Accord-
ingly, Cebpb mRNA levels correlat-
ed with those of both arginase 1 
(ARG1) and inducible NOS (iNOS), 
2 enzymes that are classically 
involved in MDSC-suppressive 
activity (Figure 1F), thus confirm-
ing the M-MDSC phenotype.
While the mean frequency 
of each cell subset did not signifi-
cantly change during the 6-week 
follow-up (Figure 1, B, C, and G), 
the absolute numbers of these cells 
increased in parallel with the num-
bers of cells in the urine (Figure 1H). 
Of note, the latter were higher in 
post- versus pre-BCG samples, con-
firming that BCG induces a strong 
local inflammation involving a variety of immune cells (Figure 1H).
To address the possible involvement of bladder tumors or 
BCG in M-MDSC induction, peripheral blood mononuclear 
cells (PBMCs) from healthy donors (HDs) were cocultured with 
Bu68.8 (non-muscle–invasive) or T24 (muscle-invasive) BCa 
cell lines, or infected with different MOI of BCG. Both cell lines, 
as well as BCG in a dose-dependent manner, induced a down-
regulation of HLA–antigen D–related (HLA-DR) on monocytes, 
leading to an increase in the frequency of cells with an M-MDSC 
phenotype (Supplemental Figure 2, A and B). Of note, heat-killed 
BCG had a similar effect, albeit to a lesser extent, suggesting 
that infection may not be required (Supplemental Figure 2C). 
Moreover, to investigate whether the skewing toward M-MDSCs 
is specific to BCG, we tested the only other FDA-approved live 
attenuated bacterial vaccine, i.e., the Salmonella typhi strain 
Ty21a (which we recently showed to be more efficient than BCG 
for bladder tumor treatment in a mouse model [ref. 15]). As 
shown in Supplemental Figure 2C, Ty21a bacteria had a limited 
effect on the induction of M-MDSCs.
In order to assess the function of induced M-MDSCs, CD14+ 
cells were sorted from the coculture with tumor cell lines and used 
in a classical T cell suppression assay. In contrast to untreated 
monocytes, CD14+ cells previously cocultured with T24 or Bu68.8 
cell lines exerted a strong suppressive function toward CD8 and 
CD4 T cell proliferation (Supplemental Figure 2D).
to shift ILCs toward the ILC2 phenotype. Moreover, in response 
to BCG, ILC2 produced the type 2 cytokine IL-13, which mediat-
ed the recruitment and immunosuppressive function of mono-
cytic cells. These results were corroborated by gene expression 
and patient survival analysis derived from The Cancer Genome 
Atlas (TCGA) data. Altogether, our findings identify a previously 
unknown mechanism of BCG failure and suggest the existence of 
a new innate ILC2/MDSC axis that fosters an immunosuppressive 
tumor microenvironment.
Results
Characterization of immune cells present in the urine during BCG ther-
apy. An easy means for monitoring immune events in the bladder 
is to examine immune cells present in urine collected shortly after 
immunotherapeutic interventions. Thus, we performed a compre-
hensive phenotypic analysis of immune cells in urine samples from 
28 patients with NMIBC during a standard 6-week intravesical 
BCG therapy. The patients’ characteristics are described in Table 1. 
Urine samples were obtained before and 4 hours after each instilla-
tion. As expected, most of the recruited cells were neutrophils (Fig-
ure 1, A and B), but we also detected T cells (Figure 1, A and C) (with 
variable CD4/CD8 ratios between samples and patients; data not 
shown), as well as monocytic cells (Figure 1D). Interestingly, a sub-
stantial number of urine CD14+ cells showed an M-MDSC pheno-
type (i.e., CD15–CD14+CD11b+CD33+HLA-DRlo) (10, 11). These cells 
Table 1. Characteristics of NMIBC patients
Characteristics All patients Low T cell/MDSC ratio High T cell/MDSC ratio P value
No. of patients 28 14 14
Age, yr, median (IQR) 68 (62–74) 68.5 (63–80) 67 (60–73) NS (P = 0.394)A
Sex, n NS (P = 1.0)B
 Male 24 12 12
 Female 4 2 2
Previous bladder tumor history, n (%) NS (P = 0.641)C
 No previous TURB 18 (64.3) 8 (57.1) 10 (71.4)
 1 previous TURB 6 (21.4) 4 (28.6) 2 (14.3)
 ≥2 previous TURB 4 (14.3) 2 (14.3) 2 (14.3)
 No. of second TURB, n (%) 23 (82.1) 11 (78.6) 11 (78.6) NS (P = 1.0)B
 No. of positive second TURB, n (%) 12 (42.9) 7 (63.6) 4 (33.3) NS (P = 0.395)B
Tumor status, n (%) NS (P = 0.705)C
 pTa 4 (14.3) 2 (14.3) 3 (21.4)
 pT1 20 (71.4) 11 (78.6) 9 (64.3)
 pTIS 3 (10.7) 1 (7.1) 1 (7.1)
 pT2 1D (3.6) 0 1 (7.1)
 Any CIS-positive 17 (60.7) 8 (57.1) 9 (64.3) NS (P = 1)B
Grade, n (%) 
 G2 low grade 3 (10.7) 1 (7.1) 2 (14.3) NS (P = 0.487)C
 G2 high grade 11 (39.3) 7 (50) 4 (28.6)
 G3 14 (50) 6 (42.9) 8 (57.1)
No. of tumors NS (P = 0.606)C
 1 12 (42.9) 5 (35.7) 7 (50)
 2 10 (35.7) 5 (35.7) 5 (35.7)
 ≥3 6 (21.4) 4 (28.6) 2 (14.3)
AUnpaired Student’s t test; BFisher’s exact test; Cχ2 test; DThis patient was diagnosed with MIBC but refused 
cystectomy and instead received BCG therapy. IQR, interquartile range.
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although we observed trends for T cells and M-MDSCs. As the bal-
ance between effector and regulatory cells may be more relevant 
(17, 18), we then assessed for each patient the mean T cell/MDSC 
ratio in post-BCG urine samples. We segregated the patients into 
2 groups: (a) patients with higher frequencies of M-MDSCs than T 
cells (i.e., log ratio <0, n = 14) and (b) patients with higher frequen-
cies of T cells than M-MDSCs (i.e., log ratio >0, n = 14) (Figure 2D). 
Of note, the ratio measured at the earliest time point available (i.e., 
pre-BCG 1 or 2) correlated with ratios obtained at later time points 
(the mean of all post-BCG samples) from the same patients (Fig-
ure 2E), suggesting that the patient dichotomy based on the post-
BCG T cell/MDSC ratios already existed before BCG treatment 
initiation and arguing in favor of a prognostic role of the T cell/
MDSC ratio. Notably, we found that the 2 groups strongly differed 
The local T cell/MDSC balance is strongly associated with bladder 
tumor recurrence. To evaluate whether and what immune profiles 
may be involved in BCG treatment failure, we prospectively fol-
lowed the time to tumor recurrence or progression, if any, for each 
of the 28 patients. The median follow-up after the start of BCG 
treatment was 33.6 months, and the 2-year recurrence-free surviv-
al rate was 56.0% (95% CI, 34.2%–73.1%) (Supplemental Figure 
3A). Patients show similar recurrence-free survival as previously 
described in larger cohorts of patients treated with the same BCG 
strain (TICE) (6, 16). When we segregated patients into groups on 
the basis of urine frequency of neutrophils (Figure 2A), T cells (Fig-
ure 2B), and M-MDSCs (Figure 2C) (i.e., mean percentage in post-
BCG urine samples greater than versus less than the median), we 
found no significant difference in recurrence-free survival rates, 
Figure 1. Identification of immune cells infiltrating the urine during BCG therapy. Flow cytometric analysis of urine-infiltrating cells in urine samples 
obtained from 28 patients with NMIBC during the 6-week intravesical BCG therapy. Urine samples were obtained before and 4 hours after each BCG instil-
lation. Pre-BCG1 data are not shown due to low urine cell content, which is typical at that time point and does not allow for measurement of immune cell 
subsets in most patients. (A) Samples were gated on live leukocytes and neutrophils (CD15+), and CD3+ T cells (comprising both CD4+ and CD8+ T cells) were 
assessed. (B and C) The frequencies (mean ± SEM) of both cell subsets in urine are depicted during the follow-up period. (D) When gating on lineage- 
negative (i.e., CD3–CD56–CD19–) cells, M-MDSCs were identified as CD15–CD14+CD11b+CD33+HLA-DRlo. (E and F) Urine Lin–CD14+CD33+HLA-DRlo and their 
HLA-DRhi counterpart cells were sorted from 7 urine samples, and mRNA levels of CEBPB, ARG1, and INOS were measured relative to the levels detected 
in circulating LPS-activated monocytes from HDs (n = 3). Levels (mean ± SEM) of CEBPB are shown for the indicated cell subsets (E) and correlated with 
ARG1 and INOS mRNA levels (F). A 2-tailed, paired Student’s t test was performed to compare both cell populations, and Spearman’s rank correlation 
coefficients (R) and the corresponding P values are indicated on each panel in F. Lines indicate linear regression. (G) Frequencies (mean ± SEM) of urine 
M-MDSCs during the follow-up period. (H) Graphs show the mean (± SEM) of total cell numbers in pre- and post-BCG urine samples and absolute numbers 
of the indicated cells subsets in post-BCG samples. *P < 0.05, **P < 0.01, and ****P < 0.0001, by 1-way ANOVA, followed by a post test for linear trend to 
assess longitudinal changes.
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Figure 2. Recurrence-free and progression-free survival in patient groups following BCG therapy for NMIBC. Recurrence-free survival was assessed 
using the Kaplan-Meier approach in a cohort of 28 patients receiving BCG therapy (with the first instillation at month 0 and the last at month 1.5).  
Censored patients are represented by symbols. Patients were segregated into 2 groups (n = 14 patients in each group) on the basis of urine levels of  
neutrophils (A), T cells (B), or M-MDSCs (C), i.e., the mean percentage of CD15+, the mean percentage of CD3+, or the mean percentage of Lin–CD14+ 
CD11b+CD33+HLA-DRlo cells above the median (High) versus below the median (Low) in post-BCG samples (2–6 time points per patient). (D) The mean T 
cell/MDSC ratio in post-BCG urine samples identified 2 groups: patients with higher frequencies of M-MDSCs than of T cells (i.e., log ratio <0) and con-
versely (i.e., log ratio >0). (E) The T cell/MDSC ratio was measurable at early time points before BCG (1 or 2) for 10 patients and correlated with the mean 
T cell/MDSC ratios in post-BCG samples from corresponding patients. The line indicates linear regression, and Spearman’s rank correlation coefficients 
(R) and the corresponding P value are indicated. Recurrence-free survival (F) and progression-free survival (G) according to the T cell/MDSC ratio. P values 
from log-rank tests are indicated on each panel. T, T cell.
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CD4 T cells were analyzed for expression of Th1 and Th2 markers 
as well as for cytokine secretion profiles. While the proportions of 
CRTH2+ CD4 T cells were low in urine samples, they were found 
at higher levels in patients from the T/Mlo group (Supplemental 
Figure 4A). As expected, we detected high levels of the Th1 cyto-
kines IFN-γ, IL-2, and TNF-α and low levels of the Th2 cytokines 
IL-4 and IL-5 in the supernatants of urine CD4+ T cells following 
24-hour anti-CD3/CD28 stimulation (data not shown). Notably, 
patients in the T/Mlo group showed a higher Th2 to Th1 cytokine 
score (Supplemental Figure 4B). Moreover, since the Th1/Th2 bal-
ance may be regulated by tryptophan (Trp) metabolism (19, 20), 
we assessed local indoleamine 2,3 dioxygenase (IDO) activity by 
measuring the kynurenine/Trp ratio in pre- and post-BCG urine 
samples (at the fifth instillation). Accordingly, we found that the 
in terms of recurrence rates (log rank: P < 0.0001), as the median 
recurrence-free survival time following the start of BCG treatment 
was only 12.7 months in patients with a low T cell/MDSC ratio (T/
Mlo), while it was not reached in patients with a high T cell/MDSC 
ratio (T/Mhi) (median follow-up of 32.7 months in this group) (Fig-
ure 2F). We also assessed the time to progression (Supplemental 
Figure 3B). Five patients from the T/Mlo group showed tumor pro-
gression versus one patient in the other group (Figure 2G).
Type 2 immunity skewing in patients with low T cell/MDSC 
ratios. To better define the immunological profiles of these 2 
patient groups with very distinct recurrence-free survival rates, 
we analyzed Th cells (Th1 versus Th2 polarization), as well as 
their innate counterparts (i.e., including the ILCs ILC1, ILC2, and 
ILC3). Freshly isolated urine T cells were expanded in vitro, and 
Figure 3. Skewing toward ILC2 is associated with low T cell/MDSC ratios during BCG therapy for NMIBC. (A) Representative example of ILC labeling. Cells 
were gated on live lineage-negative CD127+ leukocytes (with lineage including CD3, CD14, CD56, CD19, CD11c, CD303a, CD15, CD203c, and FcεR1α). (B) Quan-
tification of ILC1 (Lin–CD127+CRTH2–c-Kit–), ILC2 (Lin–CD127+CRTH2+), and ILC3 (Lin–CD127+CRTH2–c-Kit+) among urine cells (n = 23 samples). (C) Absolute 
number of ILC2 in post-BCG samples. (D) Cocultures of PBMCs from HDs (n = 6) with the NMIBC cell line Bu68.8, BCG (MOI = 1), or medium alone for 4 days. 
Repartition of ILC1, ILC2 and ILC3 subsets as well as frequencies of total ILC are shown for each indicated conditions. (E) ILC2 frequencies in post-BCG urine 
samples from patients with high (T/Mhi, n = 10) or low (T/Mlo, n = 13) T cell/MDSC ratios, as identified in Figure 2, were compared (2-tailed Student’s t test). 
ILC2 frequencies were correlated with the T cell/MDSC ratios (F) as well as T cell (G) and M-MDSC (H) frequencies in corresponding urine samples. Lines 
indicate linear regression. Spearman’s rank correlation coefficients (R) and the corresponding P values are indicated in F–H. *P < 0.05, **P < 0.01, and 
****P < 0.0001, by 1-way ANOVA followed by Tukey’s test (B), a post test for linear trend (C), or Dunnett’s test (D) for comparison of subsets, longitudinal 
changes, or conditions versus medium, respectively.
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level of IDO activity was higher in samples from patients in the 
T/Mlo group (Supplemental Figure 4C).
We next analyzed the presence and repartition of ILCs in urine 
samples from patients during their BCG therapy. While the levels 
of type 1 and type 3 ILCs were low, we found measurable levels of 
ILC2 (Lin–CD127+CRTH2+ cells) in the urine (Figure 3, A–C). In con-
sonance with this observation, in vitro experiments using PBMCs 
from HDs (Figure 3D) showed that BCa cells and BCG were able 
to significantly augment ILC2 proportions among total ILCs, at 
the expense of ILC3 and ILC1, respectively. Moreover, only BCG 
tended to induce an increase in total ILC frequencies (Figure 3D). 
Of note, in contrast to Ty21a, heat-killed BCG also significantly 
increased the percentage of ILC2, albeit to a lesser extent compared 
with the percentage of ILC2 with live BCG (Supplemental Figure 5).
We also sought evidence to explain how ILC2 could infiltrate 
the bladder in this context. It was recently reported that ILC2 
expressed the chemokine receptor CCR4 and did so at higher pro-
portions than was observed with ILC1 or ILC3 (21). We confirmed 
that CCR4 was expressed on peripheral ILC2 from patients with 
NMIBC, and at a significantly higher frequency than was observed 
on ILC1 or ILC3 (Supplemental Figure 6A). Notably, ligands for 
CCR4 (macrophage inflammatory protein 1α [MIP-1α], mono-
cyte chemoattractant protein 1 [MCP-1], regulated on activation, 
normal T cell expressed and secreted [RANTES, also known as 
CCL5], and CCL22 [also known as MDC]) have been reported 
to be induced locally during BCG therapy (9, 22–25). Of note, we 
were able to measure CCR4 expression in ILCs from 3 urine sam-
ples during BCG therapy (Supplemental Figure 6B) and found that 
most ILC2 but also, in contrast to the periphery, most ILC1 and 
ILC3 expressed CCR4 in the urine. Altogether, these data suggest 
that CCR4 may be involved in the recruitment of ILCs in the blad-
der during BCG therapy, with a preferential enrichment in ILC2, 
since ILC2, compared with ILC1 and ILC3, express a higher pro-
portion of CCR4 in the periphery. Besides, bladder tumor cells are 
able to produce low levels of prostaglandin D2 (PGD2) (Supple-
mental Figure 6C), a chemoattractant for ILC2 (26), which could 
also contribute to the recruitment of ILC2 in the bladder, as shown 
in the inflamed lung (27).
Notably, patients in the T/Mlo group showed higher levels of 
ILC2 in the urine (Figure 3E). The negative correlation between 
the T cell/MDSC ratio and ILC2 levels (Figure 3F) is probably 
explained by a putative link between ILC2 and M-MDSCs, as ILC2 
levels positively correlated with M-MDSCs but not with T cells 
(Figure 3, G and H). Altogether, these results suggest that local 
type 2 immunity skewing is linked to the immune profile associat-
ed with BCG treatment failure.
We next evaluated ILC2 and M-MDSCs in blood from the same 
patients (i.e., BCG-treated NMIBCs) but also from patients with 
more advanced (i.e., muscle-invasive BCa [MIBC]) at the time 
of cystectomy (Supplemental Table 1). As compared with HDs, 
patients with NMIBC had normal levels of circulating M-MDSCs 
and ILC2 (Figure 4, A and B), with no difference between the 
T/Mlo and T/Mhi groups (data not shown). In contrast, patients 
with MIBC showed increased peripheral blood levels of both cell 
subsets (Figure 4, A and B). Of note, the proportion of ILC2, but 
not ILC1 or ILC3, was positively correlated with M-MDSC levels 
in the blood of MIBC patients (Figure 4C), which substantiates 
the observations in urine.
Figure 4. Peripheral M-MDSCs and ILC2 in blood from NMIBC and MIBC patients. (A and B) Ex vivo frequencies of (A) M-MDSCs (Lin–CD14+CD33+CD11b+ 
HLA-DRlo cells) and (B) ILC2 (Lin–CD127+CRTH2+) measured in PBMCs from HDs (n = 14), patients with NMIBC (n = 18), and patients with MIBC at the time  
of cystectomy (n = 22 and n = 21 for M-MDSCs and ILC2, respectively). **P < 0.01, by 1-way ANOVA followed by Dunnett’s test. (C) Peripheral M-MDSC 
levels were correlated with those of the indicated ILC subsets (n = 20). Lines indicate linear regression. Spearman’s rank correlation coefficients (R) and  
the corresponding P values are indicated.
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Potential involvement of an ILC2/IL-13/MDSC axis in BCG fail-
ure. We tested the presence of ILC2-associated cytokines in urine 
samples. While IL-4 and IL-5 were undetectable (data not shown), 
IL-13 was detected in 6 of 13 post-BCG samples corresponding to 
patients with higher frequencies of ILC2 in the urine as compared 
with those with IL-13 levels below the detection limit (Figure 5A). 
We then performed an in vitro evaluation of the propensity of ILC2 
to produce IL-13 in the context of BCG stimulation. PBMCs from 
both HDs and patients with MIBC, who showed elevated ILC2 lev-
els (Figure 4B), were stimulated with BCG for 48 hours, and we 
then measured IL-13 production in ILC2 (Figure 5B). Interestingly, 
ILC2 were strongly able to express IL-13 in response to BCG, with 
higher proportions found in ILC2 from MIBC patients compared 
with ILC2 from HDs (Figure 5C). Besides, in contrast to nonmalig-
nant urothelium (HCV-29 cell line) and to the Bu68.8 cell line, the 
MIBC cell line (TCC-Sup) significantly upregulated IL-13 expres-
sion in ILC2 from patients with MIBC (Figure 5D).
Hence, we next investigated the potential contribution of an 
ILC2/IL-13–mediated mechanism in M-MDSC recruitment and/
or induction. While IL-13 is known to alternatively activate mac-
rophages (M2) (28), the role of IL-13 in MDSC biology in humans 
remains elusive. To consider a potential effect of IL-13 on human 
M-MDSCs, we first examined whether these cells express the 
IL-13 receptor α1 (IL-13Rα1) (Figure 5E), as was recently suggested 
in a mouse study (29). As shown in Figure 5F, monocytic cells from 
both HDs and patients expressed IL-13Rα1. We observed a high-
er receptor density (a) on M-MDSCs compared with monocytes 
and (b) in urine compared with circulating M-MDSCs. We then 
investigated the role of IL-13 on monocytic cells. First, we found 
in a Transwell experiment using PBMCs from HDs that IL-13 was 
able to preferentially attract monocytes in contrast to lympho-
cytes (Figure 5G), as suggested in a previous study (30). We next 
functionally assessed whether IL-13 may confer suppressive activ-
ity to monocytic cells. Therefore, blood monocytes isolated from 
HDs were cultured in the presence of granulocyte macrophage–
CSF (GM-CSF) (as a survival factor) for 4 days, with or without 
recombinant IL-13. Cells were subsequently used in autologous T 
cell proliferation assays. Analysis of CFSE dilution in cocultured 
T cells stimulated by anti-CD3/CD28 showed that IL-13–treated 
CD14+ cells were able to significantly inhibit the proliferation of 
both CD4+ and CD8+ T cells, in contrast to untreated CD14+ cells 
(Figure 5, H–J). Phenotypic analysis of the IL-13–treated monocyt-
ic cells is shown in Supplemental Figure 7. Notably, IL-13 down-
regulated HLA-DR expression, thereby increasing the frequencies 
of HLA-DRlo cells in sorted CD14+ cells (Supplemental Figure 7, A 
and B). Of note, while CD115 (CSF1-R) was upregulated following 
IL-13 treatment in both HLA-DRhi and HLA-DRlo cells, all other 
monocyte and macrophage surface markers tested showed low-
er expression, including that of the M2 marker CD163 (Supple-
mental Figure 7C). Therefore, it seems that the ability of IL-13 to 
induce suppressive function in monocytic cells is attributable to an 
induction of M-MDSCs rather than of M2 macrophages, although 
the differences between these subsets remain unclear (11). Fur-
thermore, IL-13 transcriptionally upregulated ARG1, iNOS, and 
C/EBPβ (Supplemental Figure 7D), which were also found to be 
expressed in urine M-MDSCs from patients (Figure 1, D and E). 
Moreover, IL-13 treatment of CD14+ cells increased the secretion 
of IL-1 receptor antagonist (IL-1RA), an antiinflammatory mol-
ecule blocking IL-1 signaling, while it decreased the secretion of 
MCP-1 and IL-8, a neutrophil-recruiting cytokine known to be 
associated with successful BCG therapy in patients with BCa (31) 
(Supplemental Figure 7E).
To substantiate an IL-13–mediated mechanism in M-MDSC 
induction upon BCG treatment, we tested the effect of BCG-stim-
ulated PBMC supernatant on monocytic cells in the absence or 
presence of an anti–IL-13–blocking antibody. HD PBMCs were 
stimulated with BCG for 3 days, and supernatants were harvest-
ed. As shown in Figure 5K, IL-13 was induced upon BCG stimu-
lation. Filtered supernatants were then added onto sorted CD14+ 
cells in the presence of either an anti–IL-13–blocking antibody or 
an IgG1 isotype control. After 4 days, cells were used in a T cell 
proliferation assay as above. Interestingly, we found that T cell 
proliferation, which was lower in the presence of monocytic cells 
conditioned by BCG-treated versus untreated supernatants, was 
partially recovered when IL-13 was blocked (Figure 5, L and M).
Analyses of overall survival data from TCGA. We performed a 
large-scale analysis of bladder urothelial cancer data from TCGA 
(32). In the absence of TCGA data from patients with NMIBC, this 
analysis confirmed our findings and extended them to patients with 
MIBC. These data included tumor mRNA expression and survival 
data from 300 patients with advanced-stage tumors (T2–T4 for 
>98% of samples). We observed a counterbalancing effect of mono-
cytic cells on T cells (appraised on the basis of CD14 and CD3E gene 
expression, respectively) (Figure 6A). Accordingly, short survival 
was associated with “low CD3, high CD14” expression and long 
survival with “high CD3, low CD14” expression, while intermedi-
ate survival was observed in the scenarios of “low CD3, low CD14” 
and “high CD3, high CD14” expression (Figure 6B). Moreover, the 
association analysis of CD14 and IL-13 expression corroborated a 
link between the presence of IL-13 in the tumor and a recruitment 
of CD14-expressing cells (Figure 6C). Finally, a counterbalancing 
effect holds between T cells and the presence or absence of IL-13 in 
the tumor, as the shortest survival was found in patients with low T 
cell infiltration, together with detectable IL-13 (Figure 6D).
While CD3 expression accurately defines T cells, 1 single 
marker (CD14) is not sufficient to identify M-MDSCs, so that the 
influence of M-MDSCs cannot be fully deconvoluted in TCGA 
data. Also, one cannot exclude the possibility that IL-13 expres-
sion also captures other subtypes of immune cells that may play 
a role in patient survival. Nevertheless, these in silico analyses 
are consistent with our experimental results and suggest that the 
mechanisms uncovered in this study may broadly apply to both 
NMIBC and MIBC.
Discussion
In this prospective, longitudinal study of patients with BCa, we 
observed a gradual increase in the absolute numbers of all immune 
cell subsets tested in urine during the course of BCG immunother-
apy. In contrast to individual cell subsets, the T cell–to-MDSC 
ratio, likely preestablished before treatment, was associated with 
the clinical outcome, showing that the balance between these cell 
subsets may be critically involved in tumor recurrence, when tilt-
ed toward the M-MDSC side (Figure 7). For the first time to our 
knowledge in humans, we also identified ILC2 as new players in 
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Figure 5. IL-13 is produced by ILC2 upon BCG stimulation and is able to recruit and induce suppressive function in monocytic cells. (A) Frequencies of ILC2 in 
urine samples with undetectable (n = 7) versus detectable (n = 6) urinary IL-13 (detection limit: 5 pg/ml). (B) Representative FACS histograms of IL-13–producing 
ILC2 upon stimulation with BCG (MOI = 1) or medium alone in PBMCs from HDs (n = 6) and MIBC patients (n = 5) and (C) their quantification. (D) IL-13 production 
in ILC2 from patients with MIBC following coculture with nonmalignant urothelium (HCV-29), Bu68.8, or TCC-Sup tumor cell lines. (C and D) Statistical analysis 
was performed using a 2-tailed, paired Student’s t test to compare stimulated versus medium-only conditions and a 2-tailed, unpaired Student’s t test to 
compare patients with HDs (C) and 1-way ANOVA followed by Dunnett’s test to compare cell lines with the control condition (D). (E) Representative example of 
IL-13Rα1 labeling. (F) Levels of ex vivo IL-13Rα1 expression on the indicated monocytic cells from PBMCs obtained from HDs (n = 9), NMIBC patients (n = 18), and 
MIBC patients (n = 10) and from post-BCG urine samples (n = 8), expressed as the ratio of mean fluorescence intensity (RFI) of specific staining versus the iso-
type Ig control. A 2-tailed, paired Student’s t test was performed to compare M-MDSCs with CD14+HLA-DR+/hi cells and an unpaired Student’s t test to compare 
urine with circulating counterparts. (G) Chemotactic response of CD14+ cells and CD3+/CD19+ lymphocytes from HD PBMCs (n = 6; upper chamber) to medium 
alone or IL-13 (100 ng/ml; lower chamber) using Transwell plates. (H) Representative FACS histograms of CFSE-labeled activated T cells cultured alone or with 
purified CD14+ cells pretreated with IL-13 (IL-13–treated CD14+ cells) or not (CD14+ cells). (I and J) Quantification of the proliferation index in CD8+ (I) and CD4+ (J) 
T cells. (K) IL-13 concentration in supernatants of PBMCs (n = 8) subjected to 3 days of stimulation with BCG or no stimulation. (L) Representative example of 
CFSE-labeled activated CD8+ T cells cocultured with CD14+ cells previously conditioned with filtered supernatants of unstimulated or BCG-stimulated PBMCs in 
the presence of either anti–IL-13–blocking antibody or isotype IgG1 control (10 μg/ml each). (M) Comparison of the proliferation index in each indicated condition 
(n = 3, representative of 2 independent sets of experiments). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-tailed, paired Student’s t test (G–K) 
and 1-way ANOVA followed by Tukey’s test (M). Div, percentage of cells with at least 1 division; Ig, isotype IgG1 control; PI, proliferation index; SN, supernatant.
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While MDSCs have been extensively studied in mouse can-
cer models (10), the data are sparser with regard to their clinical 
prognostic value in human cancers (34). Most studies consistent-
ly found — mainly in peripheral blood — elevated granulocytic 
and/or monocytic MDSC levels in patients with various cancers, 
including BCa (35, 36), and the levels were often associated with 
the tumor stage (34), which is in line with our peripheral MDSC 
data. In tissue, high infiltration of CD68+ tumor–associated mac-
rophages (TAMs) was associated with a poor response to BCG 
immunotherapy (37). Notably, the beneficial versus deleteri-
ous role of the tumor-associated immune contexture (38) might 
depend on the localization of immune cell subsets, which can be 
associated with different clinical outcomes according to whether 
these subsets are assessed in the tumor core versus the invasive 
margin, or inside versus outside the tertiary lymphoid structures 
(39). Likewise, the level of CD68+ macrophages in bladder CIS 
was associated with a poor response to BCG therapy only when 
measured in the tumor, and not in the bladder lamina propria 
(40). However MDSCs, in contrast to T cells, cannot be accurately 
appraised in situ by IHC. This points out the unmet need to iden-
tify specific and sensitive markers able to reliably define MDSCs 
for in situ assessment.
The growing field of ILC research is still in its infancy for 
human cancers (41, 42), although some recent studies reported on 
ILCs in murine tumor models. ILC1, and potentially ILC3, may be 
involved in tumor immunosurveillance (43, 44). However, the role 
of ILC2 — otherwise involved in anti-helminth immunity and tis-
the tumor immune contexture. Specifically, ex vivo and in vitro 
data support the involvement of an ILC2/IL-13 axis in the recruit-
ment and induction of M-MDSCs, thus pointing to a detrimental 
role for ILC2 in the context of cancer immunotherapy (Figure 7).
Since its FDA approval in 1990, intravesical BCG is one of the 
most successful cancer biotherapies to date, and yet the mech-
anisms involved in treatment success or failure remain poorly 
understood (8). The present study ascribes a critical role to the 
local balance between T lymphocytes and myeloid suppressor cells 
in the clinical response to BCG therapy, independent of patient 
and tumor characteristics (stage and grade) (Table 1). Indeed, a 
strong prognostic value with respect to recurrence was found when 
considering the T cell–to-MDSC ratio, instead of the levels of each 
individual cell subset. We can thus speculate that effective antitu-
mor T cell activity may only be generated when T cells outnumber 
the locally recruited/induced M-MDSCs. Of note, the importance 
of the effector-to-regulatory balance was previously suggested in 
human cancers, but involved FoxP3+ Tregs instead of MDSCs (17, 
33). These findings raise the possibility that the levels of T cells and 
M-MDSCs in urine after initiation of BCG therapy may be a useful 
predictive biomarker of therapeutic efficacy. However, the fact that 
(a) the patient dichotomy based on the T cell/MDSC ratio may be 
present before the start of the therapy (Figure 2E) and that (b) this 
ratio may be linked to MIBC patient survival (Figure 6) suggest a 
prognostic role of the T cell/MDSC ratio rather than a prediction of 
BCG treatment failure. Thus, further validation of this ratio’s prog-
nostic or predictive value in a larger cohort of patients is warranted.
Figure 6. TCGA data analysis for MIBC. 
Tumor mRNA expression levels were 
obtained from TCGA for 300 patients with 
BCa. (A) Survival analysis based on the 
CD3E/CD14 expression ratio (the median val-
ue was used to split samples). (B) Patients 
were first segregated on the basis of their 
CD3 levels (below and above the median 
value), and both groups were subsequently 
divided into 2 subgroups on the basis of 
CD14 levels (below and above the respec-
tive median values in the subgroups). (C) 
Comparison of CD14 levels (normalized as 
described in the Methods section) between 
samples with detectable and undetectable 
IL13 expression levels. (D) Survival analysis 
based on CD3E (the median value was 
used to split samples) and IL13 expression 
(detectable versus undetectable expression). 
P values were determined by log-rank test 
(A, B, and D) and the Wilcoxon test (C).
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Both tumor cells and BCG may 
promote the ILC2/IL-13/MDSC axis. 
We showed that BCa cells are able to 
induce suppressive M-MDSCs in vitro, 
as was previously observed in differ-
ent cell lines from various cancers (54). 
Thus, a basal immunosuppressive level 
may exist in the bladder before treat-
ment, as supported by the correlation 
between early pre-BCG and late post-
BCG samples. Second, intravesical 
BCG stimulation triggers a substantial 
immune infiltration, including infiltra-
tion of M-MDSCs and ILC2, the com-
position of which may be the result of 
different events: modulation/prolifera-
tion of already locally present immune 
cells, recruitment from the periphery by 
urothelium-derived chemokines, and, 
in a second phase, modulation of the 
locally recruited cells. While mycobacteria are potent inducers of 
Th1 responses (55), which are required for BCG-mediated bladder 
tumor control (8), we found that BCG can also induce MDSCs, as 
shown in intradermally BCG-vaccinated mice (56). In addition, 
BCG shifted ILCs toward the ILC2 phenotype, at the expense of 
ILC1. A recent study supports this finding, reporting an increase 
in ILC2 levels in Mycobacterium leprae/HIV–coinfected patients 
compared with levels in HIV-monoinfected and healthy individu-
als (57). Further investigations may evaluate whether ILC2 skew-
ing is due to ILC2 proliferation or repolarization from another ILC 
subset, as was recently suggested (58, 59).
While induction of ILC2 following mycobacteria infection/
instillation may drive tissue repair (12, 13), these cells may be 
also involved in the pathophysiology of diseases such as cancer, 
in which type 1 immunity is required. In BCa, besides inducing 
a strong Th1 response, which may depend on preexisting BCG- 
specific adaptive immunity (60), BCG may also amplify a pre-
established immunosuppressive tumor contexture containing 
MDSCs and ILC2. This needs to be compensated by a higher 
BCG-induced T cell infiltration, without which patients experi-
ence rapid tumor recurrence.
While immunotherapy using an anti–PD-L1 antibody was 
recently found to show clinical efficacy in advanced metastatic BCa, 
with a breakthrough status designated by the FDA (61), new combi-
nation treatments are urgently needed for NMIBC to improve BCG 
therapy and lower BCG failure rates (62). This study highlights the 
crucial need to restrain the tumor-induced “immunosuppressive 
switch” (63) by targeting MDSCs to tilt the balance in favor of T 
cells. A number of compounds were found to target MDSCs (10, 
11). One of these compounds, doxorubicin, may be of interest, as 
it selectively targets monocytic MDSCs in humans (64). However, 
in light of our results, all-trans retinoic acid (ATRA, also known as 
vitamin A) may be an ideal candidate treatment on the basis of the 
following properties: (a) this compound is also known to eliminate 
MDSCs and thus to augment antigen-specific T cell responses 
(65), including in cancer patients (66); (b) Spencer et al. recently 
reported that vitamin A strongly restrains ILC2 levels, particularly 
sue homeostasis — might be detrimental in the context of tumors, 
as recently suggested in a mouse cancer model (29). Interesting-
ly, we identified ILCs both locally and in the periphery in patients 
with BCa and observed a skewing toward a group 2 ILC pheno-
type that was associated with a worsening of the disease. A recent 
study reported that murine tissue-resident ILC2 expand locally 
in inflammatory conditions (45). Accordingly, bladder tumors 
and intravesical BCG stimulation may favor ILC2 proliferation/
induction in the bladder, as supported by in vitro data. An import-
ant finding in our study was the positive correlation between ILC2 
and M-MDSC levels, both locally during BCG therapy and in the 
blood of patients with MIBC. Our data suggest that IL-13 is a link 
between both cell subsets, as (a) M-MDSCs recruited to the blad-
der highly expressed the IL-13Rα1; (b) ILC2 were prone to secrete 
IL-13 in response to BCG and tumor cells in vitro; (c) urine samples 
with detectable IL-13 corresponded to samples with higher ILC2 
frequencies; and (d) IL-13 was found to both preferentially recruit 
and induce suppressive function in monocytic cells in vitro. IL-13 
is a type 2 cytokine involved in antiparasite immunity, fibrosis, and 
asthma (46) and is known, like IL-4, to induce the so-called alter-
native activation of macrophages toward the M2 phenotype (28). 
M2-like TAMs and MDSCs are not clearly demarcated entities 
and thus exhibit many common characteristics, notably the abil-
ity to favor a tumor-supporting and immune-tolerogenic micro-
environment (11). Several mouse studies documented the role of 
IL-13 in the upregulation of ARG1 (47), an enzyme that we found 
highly expressed in urine M-MDSCs and that was induced follow-
ing IL-13 treatment in monocytic cells in vitro. Murine MDSCs 
are significantly more suppressive when cultured with IL-13, and 
this effect is attributed to ARG1 upregulation (48). Accordingly, 
human M-MDSCs from head and neck cancer patients were found 
to exert a suppressive function via ARG1 (49). Elevated IL-13 lev-
els, concomitant with increased MDSC, M2, and/or ARG1 levels, 
were reported in human gastrointestinal cancers (50, 51). More-
over, an ILC2/IL-13/M2 axis was recently reported in mouse 
models of parasitic infections (52, 53) and of breast cancer (29), 
supporting our results.
Figure 7. Putative model of a suppressive axis involved in BCa recurrence. Schematic representation 
of the immune profiles associated with a high or low risk of bladder tumor recurrence. Interactions 
between tumor cells or BCG and immune cell subsets that are proposed to play an important role in 
the disease outcome are indicated. Both tumor and BCG can directly or indirectly recruit MDSCs and 
T cells locally, as well as recruit and activate ILC2 to produce IL-13 that can amplify MDSC recruitment 
and induction. Finally, the resulting balance between MDSC and T cell levels may be a critical factor 
regulating tumor recurrence.
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Cy7 (Bu15); anti–CD15-PE/Cy7 (W6D3); anti–CD163-PE (GHI/61); 
anti–CD64-PerCP/Cy5.5 (10.1); and anti–CD68-AF647 (Y1/82A) (all 
from BioLegend); anti–CD3-PE/AF610 (7D6); anti–CD19-PE/AF610 
(SJ25C1); anti–CD56−PE/Texas Red (MEM-188); and anti–CD8-PE/
AF610 (3B5) (all from Invitrogen, Thermo Fisher Scientific); anti–CD4-
APC/H7 (RPA-T4); anti–CD127-AF647 (HIL-7R-M21); anti–CD203c-
BV421 (NP4D6); anti–CD80-APC/H7 (L307); anti–CD115(CSF-1R)-
BB515 (9-4D2); and anti–CCR4-PE/Cy7 (1G1) (all from BD Biosciences); 
and anti–IL-13Rα1–PE (419718) (from R&D Systems).
Cells were stained for surface antigens for 20 minutes at 4°C, and 
an amine reactive dye (Aqua LIVE/DEAD Stain Kit; Life Technologies, 
Thermo Fisher Scientific) was used for dead cell exclusion according 
to the manufacturer’s instructions. Fc-Receptor Blocking Reagent 
(Miltenyi Biotec) was used to increase staining specificity by blocking 
unwanted binding of antibodies. Sample acquisition was performed 
on the Gallios Flow Cytometer (Beckman Coulter), and data were ana-
lyzed using FlowJo software.
Intracellular cytokine staining. Cells were stimulated with BCG 
(MOI = 1) for 48 hours, and 2.5 μg/ml brefeldin A was added for the 
last 16 hours of culture. Staining for cell-surface markers was carried 
out as described above, and cells were then fixed. Intracellular staining 
was performed with APC-conjugated anti–IL-13 mAb (JES10-5A2; BD 
Pharmingen) for 30 minutes at 4°C in 0.1% saponin (Sigma-Aldrich).
Cell lines and bacteria. Bu68.8 is a noninvasive BCa cell line 
isolated from a patient with a TaG2 tumor at the urology depart-
ment of the University of Lausanne Hospital. T24 and TCC-Sup are 
invasive urothelium carcinoma cell lines corresponding to histolog-
ical grades  G3 and G4, respectively (71) (gift of G.N. Thalmann, 
Inselspital, Bern, Switzerland). HCV-29 is a nonmalignant cell line 
derived from normal urothelium (71) (gift of Anna Lityńska, Jagiel-
lonian University, Kraków, Poland). For the cocultures, tumor cells 
were seeded to achieve confluence by the end of the experiment 
as determined beforehand (e.g., a ratio of approximately 1:20 with 
PBMCs in 4-day-long experiments).
Bacteria used for in vitro experiments were obtained by resuspen-
sion in PBS of the lyophilized content of clinically available oncoTICE 
BCG vials and Vivotif Ty21a capsules.
Suppression assays. Monocyte isolation was performed using the 
Dynabeads FlowComp Human CD14 Kit (Invitrogen) from cryopre-
served PBMC or as previously described (72) from fresh blood (>85% 
purity). CD14+ cells were cultured for 4 days with 400 U/ml GM-CSF 
(ImmunoTools) in the presence or absence of 100 ng/ml recombinant 
human IL-13 (BioLegend), or with filtered supernatant (70 %) from 
PBMCs stimulated or not for 72 hours with BCG (MOI = 1). When 
indicated, anti–IL-13–neutralizing antibody or the corresponding IgG1 
isotype control (10 μg/ml; BioLegend) was added. Autologous T cells 
were isolated from PBMCs using the Dynabeads FlowComp Human 
CD3 Kit (Invitrogen, Thermo Fisher Scientific), stained using 5 μM 
CFSE for 5 minutes at room temperature, and washed twice with ice-
cold PBS containing 5% FCS. CD14+ cells were cocultured for 4 days 
with CFSE-labeled T cells at a 1:1 ratio in 96-well pates previously 
coated with 1 μg/ml anti-CD3 (OKT3) antibody and soluble anti-CD28 
(Biolegend) (1 μg/ml) and IL-2 (150 U/ml; Roche). Proliferation of 
CFSE-labeled cells was assessed by flow cytometry after surface stain-
ing for CD3, CD4, and CD8. The proliferation index (total number of 
divisions divided by the number of cells that went into division) was 
assessed using the FlowJo Proliferation Platform.
ILC2 that produce IL-13 (67); and (c) a meta-analysis showed that 
vitamin A plays a protective role in BCa (68), and ATRA treatment 
was found to significantly improve survival and recurrence rates in 
NMIBC patients (69). Furthermore, a combination of depletion or 
attenuation of MDSCs and concomitant stimulation of effector T 
cells may be of interest. In this regard, programmed death 1 (PD-1) 
and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) combi-
nation blockade has proven to increase the T cell–to-MDSC ratio in 
melanoma tumors in mice (18).
The present study highlights the importance of the immune 
microenvironment in the clinical outcome of BCG-treated super-
ficial BCa and suggests a possible new role for ILC2 in human 
cancer. We propose that the ILC2/IL-13 axis is a mechanism driv-
ing an immunosuppressive microenvironment that is critically 
involved in the failure of BCG immunotherapy (Figure 7). Such a 
microenvironment could also influence the mortality of patients 
with more advanced cancer, as suggested by our analysis of BCa 
data from TCGA. Altogether, these results imply that M-MDSCs 
and novel pathways, such as IL-13/IL-13R signaling or ILC polar-
ization, may represent attractive targets for potentiating cancer 
immunotherapies.
Methods
Study populations. Twenty-eight patients with NMIBC were recruited 
in this prospective, longitudinal study at the University of Lausanne 
Hospital. At the time of inclusion, patients started standard BCG 
therapy involving 6 weekly intravesical instillations of TICE BCG 
(MSD: Merck Sharp & Dohme AG) (2 × 108 to 8 × 108 CFU), accord-
ing to European Association of Urology guidelines and to the decision 
of both physicians and patients. NMIBC patients’ characteristics are 
described in Table 1. Urine samples were obtained before and 4 hours 
(± 1 hour) after each instillation. Peripheral blood was also collected 
at baseline and during week 4. In addition, peripheral blood from 18 
patients with MIBC was collected at the time of cystectomy. MIBC 
patients’ characteristics are described in Supplemental Table 1. Blood 
samples were also collected from healthy volunteers (>50 years of age) 
through the local Swiss blood bank.
Clinical follow-up. Following BCG therapy, flexible cystoscopy 
and cytology were performed on a regular basis. In instances of pos-
itive cytology results and/or a visible tumor, subsequent transurethral 
resection of the bladder (TURB) allowed confirmation of the presence 
or absence of a recurrent tumor. Tumor progression was defined as the 
recurrence of a tumor at a higher stage or grade and/or worsening of 
disease, as defined in refs. 6 and 70.
Flow cytometric analysis of urine-infiltrating immune cells. Urine 
samples were centrifuged to separate cells from the urine supernatant. 
The total number of cells in urine was independent of the voided vol-
ume (our unpublished observations). The following mAbs were used 
at predetermined optimal concentrations: anti–CD45-phycoerythrin 
(PE) (2D1); anti–CD11b-allophycocyanin (APC)/eFluor 780 (ICRF44); 
anti–CD3-PerCP/Cy5.5 (SK7); anti–FcεR1α-FITC (AER-37, CRA1); anti–
CD3-PE/Cy7 (UCHT1); anti–CD14-PE/Cy7 (61D3); anti–CD19-PE/Cy7 
(SJ25C1); anti–CD303a-PE/Cy7 (201A) (all from eBioscience); anti–
CD14–Pacific Blue (HCD14); anti–CD15-PerCP/Cy5.5 (W6D3); anti–
CD33-APC (WM53); anti–HLA-DR−PE/Cy7 (L243); anti–CD15−Pacific 
Blue (W6D3); anti–CD56-PE/Cy7 (HCD56); anti–CD117 (c-Kit)-PE 
(104D2); anti-CD294(CRTH2)-PerCP/Cy5.5 (BM16); anti–CD11c-PE/
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and soluble anti-CD28 for 24 hours, and the supernatant was collect-
ed to measure IFN-γ, IL-2, TNF-α, IL-4, and IL-5 cytokines using a 
Cytometric Bead Array (BD Biosciences). For each sample, the con-
centration [i] for the cytokine i was normalized to the maximum con-
centration [i]max observed for this cytokine (Equation 1), and the Th2 
versus Th1 score (Equation 2) was determined. These equations were 
calculated as follows:
 
    (Equation 1)
 
     (Equation 2)   
Data and computational analysis in TCGA. Gene expression data 
for bladder urothelial cancer from TCGA (32) were obtained through 
release 18 from the International Cancer Genome Consortium (ICGC; 
https://icgc.org/). Gene expression was normalized to counts per mil-
lion before analysis. Survival data for the same patients were obtained 
with the FirebrowseR package in R (https://github.com/mariodeng/
FirebrowseR). We used the R survival package to plot the Kaplan- 
Meier curves and estimate the log-rank difference between the various 
groups of donors studied. The analysis was done on the overall surviv-
al of the donors. As IL-13 was not detectable in all samples, we defined 
a threshold, assuming IL13 was present in the sample when more than 
2 reads mapped to its gene.
Computation of excess CD14. The level of infiltration of the differ-
ent immune cells is in general highly correlated, such that we could 
model at first approximation the expression of CD14 as:
CD14 = α × CD45 + β
    (Equation 3)
To study the effect of IL13 on CD14, it is important to estimate how 
much the expression of CD14 differs from the expected value coming 
from the global immune infiltrate. Using all the samples, we estimat-
ed the coefficients α and β from Equation 3. Then, for each patient, 
we computed the residue of this fit: a positive residue corresponded 
to an excess of CD14 with respect to the expected amount, while a 
negative value represented a deficiency in CD14. The residues are 
shown in Figure 6C.
Statistics. Comparisons between samples and individuals or 
between conditions in the same individuals were evaluated using an 
unpaired or paired (2-tailed) Student’s t test, respectively, directly or 
after log transformation to meet normality assumptions. For multiple 
comparison analyses, 1-way ANOVA (for paired or unpaired values as 
appropriate) was performed, followed by Dunnett’s correction when 
all data were compared with a control condition, by Tukey’s correction 
when all data were compared, one with another, or by a post test for 
linear trend to assess longitudinal data. A P value of less than 0.05 was 
considered statistically significant. The Kaplan-Meier estimator was 
used to assess recurrence- and progression-free survival rates. The 
log-rank test was performed to analyze potential differences in surviv-
al rates between groups. The median follow-up time was calculated by 
using the reverse Kaplan-Meier method (77). Comparisons of patients’ 
Sorting of urine cell subsets, cDNA synthesis, and real-time qPCR. 
Lin–CD14+CD33+HLA-DRlo and Lin–CD14+CD33+HLA-DRhi cells 
were FACS sorted from post-BCG urine samples and subsequently 
tested for purity (Supplemental Figure 1). Five samples from patients 
included in the present cohort as well as two samples from patients 
receiving SII-ONCO-BCG at the University Hospital of Basel were 
tested. Dry pellets (900–10,000 cells) were then resuspended in a 
lysis-cDNA mix solution containing 6.3 μl lysis buffer (prepared as 
previously described by Gupta et al. [ref. 73]); 3 μl 5× reverse tran-
scriptase (RT) buffer (73); 1.5 μl of 0.1 M DTT (AppliChem); 0.75 μl 
of 10 mM deoxyribonucleotide triphosphates (dNTPs) (Invitrogen, 
Thermo Fisher Scientific); 0.25 μl of 100 ng/μl oligo-(dT) (Met-
abion); 0.4 μl Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase (Invitrogen, Thermo Fisher Scientific); 0.2 μl RNasin 
(Promega); and 2.6 μl RNAse-free water. To allow reverse transcrip-
tion into cDNA, samples were incubated at 37°C for 60 minutes. 
The transcriptase was then inactivated at 90°C for 3 minutes, and 
samples were stored at −80°C. Quantitative real-time PCR was per-
formed using KAPA SYBR FAST Master Mix with ROX (KAPA Bio-
systems), 200 nM of each primer, and one-twentieth of the reverse 
transcription reaction. Samples were run at least in duplicate in an 
ABI 7500 Fast Real-Time PCR Thermo Cycler (Applied Biosystems) 
with the following parameters: 3 minutes at 95°C for enzyme activa-
tion, 40 cycles at 95°C for 5 seconds and 60°C for 30 seconds, fol-
lowed by amplicon melting analysis to evaluate the specificity of the 
reaction and identify the presence of primer dimers. Β2-microglob-
ulin (B2M) was used as the reference gene, as it was previously iden-
tified as one of the most stable genes in activated monocytic cells 
(74). Primers were purchased from Microsynth, and efficiency was 
validated using cDNA serial dilutions. The primers sequences were 
as follows: B2M, 5′-CCAGCAGAGAATGGAAAG-3′ (forward) and 
5′-GATGCTGCTTACATGTCT-3′ (reverse); ARG1: 5′-ATTCTTC-
CGTTCTTCTTGACTT-3′ (forward) and 5′-AGTGTGATGTGAAG-
GATTATG-3′ (reverse); INOS: 5′-ATGCTCAGCTCATCCGCTAT-3′ 
(forward) and 5′-CACAAGGTCAGGTGGGATTT-3′ (reverse); and 
CEBPB: 5′-GCCGGTTTCGAAGTTGAT-3′ (forward) and 5′-CAA-
CAAGCCCGTAGGAACAT-3′ (reverse). Results are expressed using 
the 2–ΔΔCt method.
Measurement of soluble molecules. Cell-free urine samples were 
stored at –80°C. Cytokines were measured using a Luminex assay 
according to the manufacturer’s instructions (Thermo Fisher Sci-
entific), and tryptophan and kynurenine levels were measured by 
Metabolon Inc. using ultra-high-performance liquid chromatogra-
phy–tandem mass spectroscopy (UPLC-MS/MS) (75). The LC/MS 
portion of the platform was based on a Waters ACQUITY UPLC 
and a Thermo Scientific Q-Exactive high-resolution/accurate mass 
spectrometer. Peaks were quantified using the AUC, and relative 
kynurenine levels were divided by those of tryptophan to assess the 
K/T ratio in each sample.
Ex vivo–expanded urine T cells. Cells from urine samples were 
stimulated, either directly or following magnetic T cell enrichment, 
with PHA (1 μg/ml) and IL-2 (150 U/ml) in the presence of irradiated 
allogenic PBMCs for 2 to 4 weeks, as we previously described (76). 
When T cells successfully expanded, CD4+ T cells were isolated using 
the Dynabeads FlowComp Human CD4 Kit (Invitrogen, Thermo 
Fisher Scientific) and stained for Th1 and Th2 surface markers. The 
remaining CD4 cells were stimulated with immobilized anti-CD3 
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Supplemental Figure Legends 
 
 
Supplemental Figure 1. Sorting of urine-infiltrating monocytic cells during BCG therapy. 
LinnegCD14+CD33+HLADRlow (red) and LinnegCD14+CD33+HLADRhigh (grey) were FACS-sorted from 
post-BCG urine samples. The panels show overlay of both cell subsets after sorting (purity is indicated) 
from 1 representative sample out of 7. 
 
Supplemental Figure 2. Bladder cancer cells and BCG induce monocytic MDSC in-vitro. PBMC 
from healthy donors (at least five per conditions) were co-cultured for 4 days with Bu68.8 or T24 cells 
(A), or with BCG at 3 different doses (MOI 0.05, 0.5 and 5) (B) and the effects of Salmonella enterica 
serovar Typhi strain Ty21a and heat-killed BCG (30min at 85°C) were compared to live BCG (MOI=0.5) 
(C). Graphs show the percentage of M-MDSC (LinnegCD14+CD33+ CD11b+HLA-DRlow cells) in 
indicated conditions compared to medium only. One-way ANOVAs followed by Dunnett’s (A,B) or 
Tukey’s (C) tests: * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). (D) PBMCs were co-cultured with 
indicated cell lines for 4 days; CD14+ cells were then sorted and subsequently co-cultured with 
autologous CFSE-labeled T cells (3-day stimulation with anti-CD3/CD28). Proliferation profiles are 
depicted in histograms of CFSE fluorescence intensity in indicated T-cell populations from 1 
representative donor out of 4. Div: % cells with at least one division; PI: Proliferation Index. 
 
Supplemental Figure 3. Recurrence-free and progression-free survivals. Recurrence-free (A) and 
progression-free (B) survivals were assessed using the Kaplan-Meier approach in the cohort of 28 patients 
receiving BCG therapy (with the first instillation at month 0 and the last at month 1.5). Censored patients 
are represented by tick marks. 
 
Supplemental Figure 4. Th1/Th2 profiles of urine-infiltrating CD4 T cells during BCG therapy. (A-
B) CD4 T cells were expanded ex-vivo from twelve urine samples from patients with high (T/Mhigh, n=6) 
or low (T/Mlow, n=6) T/MDSC ratio. (A) CXCR3 and CRTH2 expression in ex vivo-expanded CD4 T 
cells. (B) Th1 cytokines (IFN-γ, IL-2, TNF-α) and Th2 cytokines (IL-4 and IL-5) were measured in the 
supernatants of activated ex vivo-expanded CD4 T cells from urine samples and a “Th2 versus Th1” score 
was calculated (see methods section) for each sample. (C) IDO activity as assessed by the Kynurenins-to-
Tryptophan (K/T) ratio in urine samples from patients of the T/Mhigh (n=9) and T/Mlow (n=9) groups. 
Two-sided t-tests: *p<0.05. 
 
 
		
Supplemental Figure 5. Induction of ILC2 by different bacteria. PBMC from 3 healthy donors were 
co-cultured with Salmonella enterica serovar Typhi strain Ty21a or with heat-killed or live BCG 
(MOI=1) for 4 days. Graph shows the percentage of ILC2 among ILC. One-way ANOVA followed by 
Tukey’s test: *p<0.05; ** p<0.01; *** p<0.001. 
 
Supplemental Figure 6. Expression of CCR4 in peripheral and urine ILC from NMIBC patients 
and production of PGD2 by tumor cell lines. (A) Ex-vivo expression of CCR4 on peripheral ILC1 
(LinnegCD127+CRTH2negc-Kitneg), ILC2 (LinnegCD127+CRTH2+) and ILC3 (LinnegCD127+CRTH2negc-
Kit+) from patients with non-muscle invasive bladder cancer (NMIBC; n=10) (one-way ANOVA 
followed by Tukey’s test: *p<0.05; **** p<0.0001). (B) CCR4 expression in ILCs from 3 urine samples 
during BCG therapy. (C) Detection of PGD2 in the supernatants of indicated bladder tumor cell lines 
(biological duplicates) in the presence or absence of 30 µM arachidonic acid (AA) as substrate (dashed 
line indicates limit of detection). 
Supplemental Figure 7. Phenotypic analysis of IL-13 treated sorted monocytes. Sorted CD14+ cells 
from PBMC of HD (n=4) were cultured for 4 days with or without recombinant IL-13 (100ng.mL-1). (A) 
Representative FACS-histograms showing HLA-DR expression in indicated conditions. (B) HLA-DR 
expression density (geometric mean fluorescence intensity, MFI) and frequency of HLA-DRlow in CD14+ 
cells. (C) Expression levels of various monocytes/macrophages markers on HLA-DRlow and HLA-DRhigh 
CD14+ cells treated or not with IL-13. (D) Relative expression of Arginase-1, iNOS and C/EBPβ 
transcripts by qPCR in CD14+ cells treated or not with IL-13. (E) Corresponding supernatants were 
harvested and soluble markers were measured by multiplex assay. Two-sided paired t-tests (B,D,E) or 
one-way ANOVAs followed by Tukey’s tests (C). * p<0.05; ** p<0.01, **** p<0.0001. 
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Supplementary Table 1. Characteristics of MIBC patients 	
Characteristics All patients 
N° of patients 23 
Age, yr, median (IQR) 71 (65-805) 
Sex, n  
Male 18 
Female 5 
Tumor status, n (%)  
pT2 6 (26.1) 
pT3 14 (60.9) 
pT4 3 (13) 
Draining lymph node status, n (%)  
Nx 5 (21.7) 
N0 10 (43.5) 
N1 4 (17.4) 
N2 4 (17.4) 
Neoadjuvant chemotherapy 10 (43.5) 		
